Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same

Patent metadata

Field	Value
Publication number	US-9493537-B2
Application number	US-201514629791-A
Country	US
Kind code	B2
Filing date	Feb 24, 2015
Priority date	Nov 30, 2009
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

First claim

The invention claimed is:

1. A compound according to the chemical structure:

wherein Y 1 is a DOTA group, a NOTA group or a HYNIC group;
X is GlyGlyNle, or X′ m -(ABC) n where X′ is

A is absent,
B is Nle,
C is absent,
m is 1,
n is 1 and
p is 7, or
a pharmaceutically acceptable salt thereof, wherein said compound is optionally complexed with at least one radioisotope selected from the group consisting of 86 Y, 90 Y, 111 In, 177 Lu, 225 Ac, 212 Bi, 213 Bi, 66 Ga, 67 Ga, 68 Ga, 64 Cu, 67 Cu, 71 As, 72 As, 76 As, 77 As, 65 Zn, 48 V, 203 Pb, 209 Pb, 212 Pb, 166 Ho, 149 Pm, 153 Sm, 201 Tl, 188 Re, 186 Re and 99m Tc.

2. The compound according to claim 1 which is complexed with a radioisotope.

3. The compound according to claim 1 wherein Y 1 is a DOTA group and said compound is complexed with a radioisotope selected from the group consisting of 166 Ho, 149 Pm, 153 Sm, 203 Pb, 212 Pb, 212 Bi, 86 Y, 225 Ac, 213 Bi, 71 As, 72 As, 76 As, 77 As, 65 Zn, 48 V and 209 Pb.

4. The compound according to claim 1 wherein Y 1 is a NOTA group and said compound is complexed with a radioisotope selected from the group consisting of 67 Ga, 68 Ga, 64 Cu, and 67 Cu.

5. The compound according to claim 1 wherein Y 1 is a HYNIC group and said compound is complexed with a radioisotope which is 99m Tc, 188 Re and 186 Re.

6. A pharmaceutical composition comprising an effective amount of a compound comprising a radioisotope according to claim 1 in combination with a pharmaceutically acceptable carrier additive or excipient for use in the diagnosis and/or treatment of melanoma.

7. The pharmaceutical composition of claim 6 , wherein said composition further comprises an effective amount of at least one agent selected from the group consisting of dacarbazine (DTIC), interleukin-2 (IL-2) and alpha- interferon.

8. A compound according to the chemical structure:

wherein Y 1 is a DOTA group, a NOTA group or a HYNIC group;
X is Nle or X′ m -(ABC) n where X′ is

A is absent,
B is Nle,
C is absent,
m is 1,
n is 1 and
p is 7, or
a pharmaceutically acceptable salt thereof, wherein said compound is optionally complexed with at least one radioisotope selected from the group consisting of 86 Y, 90 Y, 111 In, 177 Lu, 225 Ac, 212 Bi, 213 Bi, 66 Ga, 67 Ga, 68 Ga, 64 Cu, 67 Cu, 71 As, 72 As, 76 As, 77 As, 65 Zn, 48 V, 203 Pb, 209 Pb, 212 Pb, 166 Ho, 149 Pm, 153 Sm, 201 Tl, 188 Re, 186 Re and 99m Tc.

9. The compound according to claim 8 which is complexed with a radioisotope.

10. The compound according to claim 8 wherein Y 1 is a DOTA group and said compound is complexed with a radioisotope selected from the group consisting of 166 Ho, 149 Pm, 153 Sm, 203 Pb, 212 Pb, 212 Bi, 86 Y, 225 Ac, 213 Bi, 71 As, 72 As, 76 As, 77 As, 65 Zn, 48 V and 209 Pb.

11. The compound according to claim 8 wherein Y 1 is a NOTA group and said compound is complexed with a radioisotope selected from the group consisting of 67 Ga, 68 Ga, 64 Cu, and 67 Cu.

12. The compound according to claim 8 wherein Y 1 is a HYNIC group and said compound is complexed with a radioisotope which is 99m Tc, 188 Re and 186 Re.

13. A pharmaceutical composition comprising an effective amount of a compound comprising a radioisotope according to claim 8 in combination with a pharmaceutically acceptable carrier additive or excipient for use in the diagnosis and/or treatment of melanoma.

14. The pharmaceutical composition of claim 13 , wherein said composition further comprises an effective amount of at least on agent selected from the group consisting of dacarbazine (DTIC), interleukin-2 (IL-2) and alpha- interferon.

15. A compound according to the chemical structure:

wherein Y l is a DOTA group, a NOTA group or a HYNIC group;
X is GlyGlyNle, GlyGluNle, GlyGlyGlyNle, GlySerGlyNle, or X′ m -(ABC) n where X′ is

ABC is an amino acid linker wherein,
A is absent;
B is Nle;
C is absent;
m is 1,
n is 1 and
p is 7,
k is 2,
s is 0 and
i is 1 or 2, or
a pharmaceutically acceptable salt thereof.

16. The compound of claim 15 , wherein said compound is complexed with at least one radioisotope selected from the group consisting of 86 Y, 90 Y, 111 In, 177 Lu, 225 Ac, 212 Bi, 213 Bi, 66 Ga, 67 Ga, 68 Ga, 64 Cu, 67 Cu, 71 As, 72 As, 76 As, 77 As, 65 Zn, 48 V, 203 Pb, 209 Pb, 212 Pb, 166 Ho, 149 Pm, 153 Sm, 201 Tl, 188 Re, 186 Re and 99m Tc.

17. A method of diagnosing the existence or absence of melanoma in a patient at risk for melanoma comprising administering to said patient a compound according to claim 16 ; imaging said patient to determine if tissue is said patient exhibits elevated expression of MSH receptors; and diagnosing said patient as having melanoma if said tissue evidences elevated expression of MS receptors in comparison to a standard.

18. The method according to claim 17 , wherein said melanoma is metastatic melanoma.

19. The method of claim 17 , wherein said imaging is conducted using single photon emission computed tomography (SPECT) or positron emission tomography (PET).

20. A method of treating melanoma in a patient in need of therapy comprising administration to said patient an effective amount of a composition comprising the compound of claim 16 .

21. The method of claim 20 , wherein said composition is co-administered with an effective amount of at least on agent selected from the group consisting of dacarbazine (DTIC), interleukin-2 (IL-2) and alpha- interferon.

22. The compound according to claim 15 wherein X′ is

23. The compound according to claim 15 wherein X′ is

24. The compound according to claim 15 wherein X is GlyGlyNle, GlyGluNle, GlyGlyGlyNle or GlySerGlyNle.

Assignees

• Stc Unm

Inventors

• Miao Yubin
• Guo Haixun

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K51/08

  Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title